(Q41475059)

1 October 2017

1 reference

title

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses (English)

1 reference

1 October 2017

0 references

Buckley PF

1

1 reference

1 October 2017

publication date

1 May 1997

1 reference

The Journal of Clinical Pharmacology

1 October 2017

published in

1 reference

1 October 2017

volume

37

1 reference

1 October 2017

issue

5

1 reference

1 October 2017

page(s)

363-378

1 reference

Agranulocytosis during treatment with chlozapine

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Patient response and resource management: another view of clozapine treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Clozapine and risperidone: refining and extending their use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Clozapine: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Clozapine-related tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

The effects of clozapine on tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Effect of Risperidone on Hostility in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Clozapine eligibility among state hospital patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

21 January 2018

Risperidone guidelines

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Goals of antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Research update on the psychosocial treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Catching up on schizophrenia. The Fifth International Congress on Schizophrenia Research, Warm Springs, Va, April 8-12, 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

Hospitalization Rates Among Clozapine-Treated Patients: A Prospective Cost-Benefit Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04314.X

10.1002/J.1552-4604.1997.TB04314.X

21 January 2018

Identifiers

DOI

1 reference

1 October 2017

1 reference